Grant Opportunities
Funding pathways for hirudotherapy research and clinical trials
Last updated: March 14, 2026
Advancing the evidence base for hirudotherapy requires sustained research funding. This guide identifies federal, private, and international funding mechanisms relevant to leech therapy research and provides guidance on designing fundable proposals that meet contemporary evidence standards.
NIH Funding Mechanisms
NCCIH — Complementary & Integrative Health
The National Center for Complementary and Integrative Health is the primary NIH institute for hirudotherapy research. NCCIH funds studies on natural products, mind-body interventions, and traditional practices. Relevant mechanisms: R01 (investigator-initiated research, up to 5 years), R21 (exploratory/developmental, 2 years, $275K direct costs), and R34 (clinical trial planning).
NIAMS — Musculoskeletal Research
The National Institute of Arthritis and Musculoskeletal and Skin Diseases funds OA research — the strongest evidence area for hirudotherapy. A multi-center RCT for knee OA with WOMAC endpoints could align with NIAMS strategic priorities for non-pharmacologic interventions. The existing Michalsen and Andereya RCTs provide preliminary data.
NHLBI — Cardiovascular Research
The National Heart, Lung, and Blood Institute funds research relevant to the leech-to-pharmaceutical pipeline (DTIs, antiplatelet agents) and basic science on SGS cardiovascular mechanisms. Translational studies on novel SGS compounds with cardiovascular targets may qualify.
NINDS — Neurological Research
The National Institute of Neurological Disorders and Stroke funds neuroprotection and neurotrophic factor research. The neurotrophic properties of destabilase (active at 10−12 M) and SGS effects on neurite outgrowth represent basic science opportunities.
Other Federal Agencies
NSF — Biological Sciences
The National Science Foundation Biological Sciences Directorate funds basic research on leech biology: genomics, proteomics, symbiosis, antimicrobial peptides, and evolutionary biology. Proposals should emphasize fundamental discovery rather than clinical application.
DoD CDMRP — Combat Trauma
The Congressionally Directed Medical Research Programs fund combat-related medical research. Microsurgical tissue salvage — the FDA-cleared indication for medicinal leeches — has direct military relevance for blast injuries, extremity reconstruction, and digit/limb replantation in austere environments. The Reconstructive Transplant Research Program may be a relevant mechanism.
Private Foundations
BTER Foundation
The Biotherapeutics Education and Research (BTER) Foundation is dedicated to advancing research and education in biotherapy, including hirudotherapy. BTER provides grants for clinical research, educational programs, and practitioner training. As a domain-specific funder, BTER proposals can focus specifically on hirudotherapy without needing to justify the field's relevance to a broader biomedical audience.
Study Design Guidance
What Makes a Fundable Proposal
Validated Endpoints
- VAS pain — visual analog scale (0–100 mm)
- WOMAC — Western Ontario and McMaster Universities OA Index
- Tissue salvage rate — binary outcome for microsurgery
- SF-36 — quality of life measure
- Blood pressure — mmHg (objective, reproducible)
IRB Considerations
- Informed consent for biological therapy with infection risk
- Antibiotic prophylaxis protocol in study design
- Data safety monitoring board for multi-site trials
- Animal welfare considerations (single-use euthanasia)
- Inclusion/exclusion criteria for anticoagulant interactions
International Funding
DFG (Germany)
The Deutsche Forschungsgemeinschaft has funded the most important hirudotherapy RCTs to date (Michalsen, Backer, Hohmann). Germany's strong naturopathic medicine tradition (Heilpraktiker) and academic centers at Duisburg-Essen and Charite Berlin provide an established infrastructure for clinical trials.
RFBR (Russia)
The Russian Foundation for Basic Research funds leech biology and SGS biochemistry. Russian laboratories have produced critical basic science (Baskova, Zavalova, Babenko). International collaborations that combine Russian biological expertise with Western trial methodology are a strategic opportunity for the field.
ASH Research Priorities
ASH has identified the following as highest-priority research targets: (1) a multi-center RCT for knee osteoarthritis with ≥200 patients, WOMAC primary endpoint, and 12-month follow-up; (2) standardized treatment protocols with dose-response data (number of leeches, session frequency, total course); (3) cost-effectiveness analysis comparing hirudotherapy with intra-articular injections; and (4) a national registry for microsurgery outcomes to expand the Tier A evidence base. ASH is available to provide letters of support for grant applications aligned with these priorities.